Amendments to the Specification:

Please insert the following paragraph on page 1, between the Title of the Invention and the Field of the Invention:

[0001.0] This application is a continuation of U.S. Application No. 09/849,402, filed May 4, 2001, which is a continuation of U.S. Application No. 09/269,682, filed December 14, 1999, which was a national stage application based on International Application No. PCT/US97/18575, filed October 15, 1997, which claims priority from U.S. Provisional Application No. 60/028,167, filed October 16, 1996, and U.S. Provisional Application No. 60/052,920, filed July 15, 1997.

Please replace paragraph [0002] with the following amended paragraph:

[0002] The following references are referred to by numbers in brackets ([]) at the relevant portion of the specification.

- 1. Ahern and Manning, Eds., Stability of Protein Pharmaceuticals, A: Chemical and Physical Pathways of Protein Degradation, Plenum Press, New York, 1992.
- 2. Wang et al., 1988, J. Parenteral Science and Technology 42: S4-S26.
- 3. Deetz et al., 1988, Trends in Biotechnol. 6: 15-19.
- 4. Chin et al., 1994, Biotechnol. Bioeng. 44: 140-145.
- 5. Klibanov, 1989, TIBS 14: 141-144.
- 6. Zaks et al., 1984, Science 224:1249-1251.
- 7. Affleck et al., 1992, Proc. Natl. Acad. Sci. USA 89:1100-1104.
- 8. Zaks et al., 1988, J. Biol. Chem. 263:8017-8021.
- 9. Volkin et al., 1991, Biotechnol. Bioeng. 37: 843-853.
- 10. Guagliardi et al., 1989, Chimicaoggi 31-36.
- 11. Paulaitis et al., 1992, Annals New York Acad. Sci. 672:278-282.
- 12. Matsuura et al., 1993, J. Amer. Chem. Soc. 115:1261-1264.

- 13. Zaks et al., 1988, J. Biol. Chem. 263:3194-3201.
- 14. Prestrelski et al., 1993, Biophys. J. 65:661-671.
- 15. Zhang et al., 1995, Pharm. Res. 12, 1447-1452.
- 16. Singer et al., "The Properties of Protein in Non-Aqueous Solvents," 1962, Adv. Prot. Chem. 1-68.
- 17. Volkin et al., 1991, Biotechnol. Bioeng. 37: 843-853.
- 18. Aldercreutz et al., 1987, Biocatalysis 1: 99-108.
- 19. Guinn et al., 1991, Biotechnol. Bioeng. 37: 303-308.
- 20. Desai et al. 1995, J. Am. Chem. Soc. 117: 3940-3945.
- 21. Yu et al., 1996, J. Pharm. Sci. 85: 396-401.
- 22. Burke et al., 1989, J. Am. Chem. Soc. 111: 8290-8291.
- 23. Kanerva et al., 1989, J. Am. Chem. Soc. 111: 6865-6866.
- 24. Desai et al., 1994, J. Am. Chem. Soc. 116:9420-9422.
- 25. Chang et al., January 1996, Pharm. Tech. 80-84.
- 26. Manning et al., 1989, Pharm. Res. 6: 903-918.
- 27. Hageman, 1988, Drug Dev. Ind. Pharm. 14:2047-2070.
- 28. Bell et al., 1995, Biopolymers 35: 201-209.
- 29. Meadows, 1996, U.S. Patent No. 5,480,914.
- 30. Meadows, 1996, U.S. Patent No. 5,518,731.
- 31. Hageman, 1994, International Publication No. WO94/06452.
- 32. Hofland et al., 1996, Proc. Natl. Acad. Sci. 93:7305-7309.
- 33. Sullivan, 1996, BioPharm September: 50-51 and 65-66.
- 34. Huang et al., 1996, International Publication No. WO96/27393.
- 35. Debs et al., 1993, International Publication No. WO93/25673.

- Lemoine and Cooper, Ed., Gene Therapy, Bios Scientific Publishers,
 Oxford, UK, 1996.
- 37. Debs et al., 1993, International Publication No. WO93/24640.
- 38. Gibco technical report.
- 39. Boehringer Mannheim technical report.
- 40. Avanti polar lipid technical report.
- 41. Szoka et al., 1996, International Publication No. WO96/41873.
- 42. Huang et al., 1990, Nucl. Acids Res. 18(4): 937-947

Please replace paragraph [0011] with the following amended paragraph:

[0011] DNA complexed with cationic lipids and/or liposomes has been shown to be an efficient means of transfecting a variety of mammalian cells. Such complexes are simple to prepare and may be used with a wide variety of DNA's and RNA's with little restriction to the size of nucleic acid. They have the ability to transfect many different cell types with efficiency and are not immunogenic [32, 33, 35, 36]. Current nucleic acid formulations, including DNA/liposome and RNA/liposome complexes, must be mixed shortly before administration, resulting in inconvenience in manufacture, shipping, storage and administration [35, <u>37</u> 37-40]. Frequently, these two-part formulations are not very highly concentrated, requiring the administration of large volumes of solution. Dry powder formulations containing lyophilized nucleic acid/liposome complexes have also been used [34, 41], but they require reconstitution with suitable aqueous solution just prior to administration. Aqueous complexes are inherently unstable and lose most, if not all, of their transfection activity within hours or a few days [41].